Acta Med. 2011, 54: 117-121
https://doi.org/10.14712/18059694.2016.32
Factor V Leiden Mutation and its Impact on Pregnancy Complications
References
1. J Matern Fetal Med 1998; 7:227–286.
< F, Romero R, Joist H, Kraus FT. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. https://doi.org/10.1002/(SICI)1520-6661(199811/12)7:6<277::AID-MFM5>3.0.CO;2-3>
2. Nature 1994; 369:64–67.
< RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. https://doi.org/10.1038/369064a0>
3. Bourjeily G, Paidas M, Khalil H, Rosene-Montella K, Rodger M. Pulmonary embolism during pregnancy. Lancer 2009; 375(suppl 9713):500–512.
4. J Clin Endocrinol Metab 2002; 87:2954–2959.
< GJ, Watson AL, Hempstock J, Skepper JN, Jauniaux E. Uterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy. https://doi.org/10.1210/jcem.87.6.8563>
5. Blood 1998; 91(suppl 4):1135–1139.
WP, Lee CK, Kwong YL, Lam CK, Liang R. A Novel Mutation of Arg306 of Factor V Gene in Hong Kong Chinese.
6. Br J Haematol 2007; 140:236–240.
P, Walker ID, Govan L, Wu O, Greer IA. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on hemorrhagic an thrombotic pregnancy outcomes.
7. Best Pract Res Clin Obstet Gynaecol 2009; 23(6):751–764.
< P, Marton T. Pathological assessment of intrauterine growth restriction. https://doi.org/10.1016/j.bpobgyn.2009.06.006>
8. Proc Natl Acad Sci USA 1993; 90:1004–1008.
< B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. https://doi.org/10.1073/pnas.90.3.1004>
<PubMed>
9. Proc Natl Acad Sci USA 1993; 90:1004–1008.
< B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. https://doi.org/10.1073/pnas.90.3.1004>
<PubMed>
10. Am J Obstet Gynecol 1999; 181:975–980.
< CJM, Bloemenkamp KWM, Duvenkot EJ, Helmerhorst FM, Bertina RM, Vander Meer F et al. Preeclampsia and genetic risk factors for thrombosis: A case-control study. https://doi.org/10.1016/S0002-9378(99)70335-2>
11. Obstet Gynecol 2005; 106:517–524.
< D, Miller C, Sibai B, Spong CY, Thom E, Wendel JrG. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. https://doi.org/10.1097/01.AOG.0000173986.32528.ca>
12. Eur J Obstet Gynecol Reprod Biol 2001; 95:213–217.
< MM, Schuiling GA. Preeclampsia and the inflammatory response. https://doi.org/10.1016/S0301-2115(00)00493-0>
13. Placenta 2004; 25:730–734.
< E, Tiovonen S, Romppanen EL, Helisalmi S, Keski-Nisula L, Punnonen K, Heinonen S. M385T polymorphism in the factor V gene, but not Leiden mutation, is associated with placental abruption in Finnish women. https://doi.org/10.1016/j.placenta.2004.02.006>
14. Am J Obstet Gynecol 2001; 184:1211–1217.
< YJ, Williamson RA, Murray JC, Andrews J, Pietscher JJ et al. Genetic susceptibility to preeclampsia: Roles of cytosine-to-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68–base pair insertion at nucleotide 844 of the gene for cystathionine β-synthase, and factor V Leiden mutation. https://doi.org/10.1067/mob.2001.110411>
15. J Am Soc Hypertens 2008; 2(6):484–494.
< MD, Taler SJ, Cunningham FG. Hypertension in pregnancy. https://doi.org/10.1016/j.jash.2008.10.001>
16. Obstet Gynecol 1999; 94:595–599.
P, Dahlbäck B, Maršál K. Thrombotic risk during pregnancy: A population study.
17. Obstet Gynecol 2001; 98:1041–1044.
A, Schreiber L, Rosner S, Lessing JB, Eldor A, Kupferminc MJ. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia.
18. Am J Obstet Gynecol 2003; 188(4):981–985.
< LME, Craigie S, Taylor RS, Ward Ch, McLintock C, North RA. Inherited thrombophilias are not increased in “idiopathic” small-for-gestational-age pregnancies. https://doi.org/10.1067/mob.2003.218>
19. Hypertension 2005; 46:1270–1274.
< G, Parretti E, Marozio L, Pizzi C, Lojacono A, Frusca T et al. Thrombophilia is significantly associated with severe preeclampsia. https://doi.org/10.1161/01.HYP.0000188979.74172.4d>
20. Hypertension 1999; 33:1338–1341.
< KM, Fu B, Ferraro F, Lewis I, Downing S, Morris NH. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort. https://doi.org/10.1161/01.HYP.33.6.1338>
21. J Thromb Haemost 2005; 3:1603–1610.
< I, Vormittag R. Thrombophilia and pregnancy outcome. https://doi.org/10.1111/j.1538-7836.2005.01417.x>
22. BJOG 2003; 110:462–466.
< M, Happach C, Maršál K, Dahlbäck B, Lindquist PG. Factor V Leiden in pregnancies complicated by placental abruption. https://doi.org/10.1046/j.1471-0528.2003.02369.x>
23. Aust N Z J Obstet Gynaecol 2007; 47(4):297–301.
< M, Lubušký M, Slavík L, Hrachovec P, Zielina P, Kudela M, Lindquist PG. Frequency of selected thrombophilias in women with placental abruption. https://doi.org/10.1111/j.1479-828X.2007.00741.x>
24. Lancet 2003; 361:901–908.
< E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. https://doi.org/10.1016/S0140-6736(03)12771-7>
25. Placenta 2003; 24(suppl A):S21–S27.
< CWG, Sargent IL. Preeclampsia, the Placenta and the Maternal Systematic Inflammatory Response – A Review. https://doi.org/10.1053/plac.2002.0930>
26. Br J Haematol 2006; 132:171–196.
< L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GD, Walker ID, Greaves M, Brenkel I, Regan L et al. Thrombophilia in pregnancy: a systematic review. https://doi.org/10.1111/j.1365-2141.2005.05847.x>
27. Thromb Haemost 1996; 75:387–388.
BJ, Friedrich PW, Simioni P. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women.
28. Lancet 2005; 365:785–799.
< B, Dekker G, Kupferminc M. Pre-eclampsia. https://doi.org/10.1016/S0140-6736(05)71003-5>
29. Hum Reprod Update 2000; 6(suppl 3):301–306.
< V, Aleandri V, Morini F. The impact of Factor V Leiden mutation on pregnancy. https://doi.org/10.1093/humupd/6.3.301>
30. Hum Reprod 2002; 17:446–451.
< MD, Awartani KA, Robinson WP. Cytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study. https://doi.org/10.1093/humrep/17.2.446>
31. Obstet Gynecol 2004; 104:784–788.
< EA, Silver RM, LaCoursiere DY, Porter TF, Branch DW. Recurrent fetal aneuploidy and recurrent miscarriage. https://doi.org/10.1097/01.AOG.0000137832.86727.e2>
32. The GOPEC Consortium. Disentangling fetal and maternal susceptibility for preeclampsia: A British multicenter candidate-gene study. Am J Hum Genet 2005; 77:127–131.
33. Acta Obstet Gynecol Scand 2006; 85(6):700–705.
< M, Nuutila M, Hiilesmaa V, Paavonen J, Ylikorkala O. Clinical presentation and risk factors of placental abruption. https://doi.org/10.1080/00016340500449915>
34. Am J Reprod Immunol 1989; 21:123–131.
< DA, Harris EN. Antiphospholipid antibodies and reproduction. https://doi.org/10.1111/j.1600-0897.1989.tb01016.x>
35. Eur J Obstet Gynecol Reprod Biol 2004; 113:36–40.
< E, Borg JY, leCam-Duchez V, Goffinet F, Degré S, Fournet P. Thrombophilia and fetal growth restriction. https://doi.org/10.1016/j.ejogrb.2003.06.007>
36. Blood 1998; 91:1140–1144.
D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C.
37. Blood 2006; 107:4666–4668.
< A, Mor-Cohen R, Kovalsky V, Kornbrot N, Conrad J, Peyvandi F et al. Prothrombin 20210G>A is ancestral prothrombotic mutation that occurred in white approximately 24,000 years ago. https://doi.org/10.1182/blood-2005-12-5158>